Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Genscript Biotech Corporation
  6. News
  7. Summary
    1548   KYG3825B1059

GENSCRIPT BIOTECH CORPORATION

(1548)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genscript Biotech : Launches Closed-End Double-Stranded DNA Service for CRISPR

11/29/2021 | 11:51pm EST
Nov 11, 2021

PISCATAWAY, NEW JERSEY, Nov. 11, 2021 - GenScript USA Inc., the world's leading life science research tools and services provider, announced today that it has launched the GenWand™ Double-Stranded DNA (dsDNA) Service for the manufacture of CRISPR knock-in homology- directed repair (HDR) templates in T cell engineering. Closed-end dsDNA enables researchers to perform gene knock-in with higher efficiency and lower toxicity than traditional PCR methods and is ideally suited for large-scale screening and scale-up in cell and gene therapy.

"We continue to believe that non-viral vector delivery has clear advantages - including safety - in CRISPR/Cas applications for gene and cell therapy," said Ray Chen, PhD, president of GenScript USA Life Science Group, Inc. "Our GenWand closed-end DNA service offers better performance and scalability to researchers, and represents an important expansion of our portfolio of services for gene and cell therapy."

GenScript's GenWand dsDNA service manufactures covalently closed-end linear DNA to help increase the stability of dsDNA by limiting endonucleases' digestion of the dsDNA once entering cells. It also mitigates non-homologous end joining risk and increases knock-in accuracy when using CRISPR homology-directed repair machinery. Made via a proprietary production process, GenScript's dsDNA is available from micrograms to grams, and in 2-10 kb sequences. Various quality grades are available from research grade to basic GMP.

This new service complements a growing portfolio of offerings for CRISPR/Cas genome editing, including the GenExact™ ssDNA Service, and Phase Appropriate GMPsgRNA through its CRISPR Synthetic Guide RNA Services. In an ongoing collaboration with the University of California, San Francisco, GenScript has delivered an approximately 2.3Kb ssDNA for T cell engineering with non-viral genome targeting using long DNA sequences. The company delivers more than 10,000 sgRNA annually to clients globally and has manufactured more than 30+ phase appropriate GMP sgRNA batches for biopharma clients located in China.

"As a global leader in gene synthesis, GenScript is committed to offering a one-stop-shop to customers developing new immunotherapies to fight cancer," added Chen. "We are continually expanding our portfolio of innovative new products and services in this field and expect to support additional projects at the basic GMP level for investigational new drug applications and early-stage clinical trials."

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31st, 2020, GenScript's products and services have been cited by 52,500 peer-reviewed journal articles worldwide.

For more information visit www.genscript.com.

Michael Lau, PhD
Director of Corporate Strategy
GenScript USA Inc.
818-232-6265
732-885-9188 ext. 249
michael.lau@genscript.com

Media
Susan Thomas
Principal, Endpoint Communications
(619) 540-9195
susan@endpointcommunications.net

Disclaimer

GenScript Biotech Corporation published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 04:50:04 UTC.


ę Publicnow 2021
All news about GENSCRIPT BIOTECH CORPORATION
01/11Genscript Biotech Awards Restricted Shares to CEO
MT
2021Nasdaq-listed Legend Biotech Raises $345 Million in Share Offering
MT
2021Genscript Biotech Subscribes for $90 Million Shares in Legend Bio's ADS Public Offering
MT
2021GenScript Biotech Corp. Expands to the United Kingdom with New Offices and Logistics Ce..
CI
2021NORTH AMERICAN MORNING BRIEFING : Stocks Seen on Hold as Fed Looms
DJ
2021Hong Kong-Listed Chinese Biotech Stocks Slide on U.S. Sanction Fears
DJ
2021Nasdaq-listed Legend Biotech Plans $300 Million in Stock Offering; Parent Genscript Sha..
MT
2021Genscript Biotech's Nasdaq-Listed Arm Presents Clinical Trial Data for Investigational ..
MT
2021Partner of Genscript's Nasdaq-Listed Arm Submits New Drug Application for Multiple Myel..
MT
2021GENSCRIPT BIOTECH : Launches Closed-End Double-Stranded DNA Service for CRISPR
PU
More news
Financials (USD)
Sales 2021 510 M - -
Net income 2021 -136 M - -
Net cash 2021 513 M - -
P/E ratio 2021 -425x
Yield 2021 -
Capitalization 64 728 M 8 308 M -
EV / Sales 2021 126x
EV / Sales 2022 81,0x
Nbr of Employees 4 558
Free-Float 61,4%
Chart GENSCRIPT BIOTECH CORPORATION
Duration : Period :
Genscript Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSCRIPT BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 30,80 $
Average target price 4,76 $
Spread / Average Target -84,6%
EPS Revisions
Managers and Directors
Zhenyu Liu Chief Executive Officer
Ye Wang President, COO & Executive Director
Jian Ge Meng Chairman & Secretary
Hong Xin Guo Independent Non-Executive Director
Zu Mian Dai Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GENSCRIPT BIOTECH CORPORATION-10.72%8 638
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684